Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(7):930–934. doi: 10.1038/sj.bjc.6690445

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

N E Eaton 1, G K Reeves 1, P N Appleby 1, T J Key 1
PMCID: PMC2363051  PMID: 10362098

Abstract

This paper presents a quantitative review of the data from eight prospective epidemiological studies, comparing mean serum concentrations of sex hormones in men who subsequently developed prostate cancer with those in men who remained cancer free. The hormones reviewed have been postulated to be involved in the aetiology of prostate cancer: androgens and their metabolites testosterone (T), non-SHBG-bound testosterone (non-SHBG-bound T), di-hydrotestosterone (DHT), androstanediol glucuronide (A-diol-g), androstenedione (A-dione), dehydroepiandrosterone sulphate (DHEAS), sex hormone binding globulin (SHBG), the oestrogens, oestrone and oestradiol, luteinizing hormone (LH) and prolactin. The ratio of the mean hormone concentration in prostate cancer cases to that of controls (and its 95% confidence interval (CI)) was calculated for each study, and the results summarized by calculating the weighted average of the log ratios. No differences in the average concentrations of the hormones were found between prostate cancer cases and controls, with the possible exception of A-diol-g which exhibited a 5% higher mean serum concentration among cases relative to controls (ratio 1.05, 95% CI 1.00–1.11), based on 644 cases and 1048 controls. These data suggest that there are no large differences in circulating hormones between men who subsequently go on to develop prostate cancer and those who remain free of the disease. Further research is needed to substantiate the small difference found in A-diol-g concentrations between prostate cancer cases and controls. © 1999 Cancer Research Campaign

Keywords: prostate cancer, steroid hormones, androstanediol glucuronide, prospective studies, review

Full Text

The Full Text of this article is available as a PDF (93.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl. 1990;201:3–23. [PubMed] [Google Scholar]
  2. Barrett-Connor E., Garland C., McPhillips J. B., Khaw K. T., Wingard D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990 Jan 1;50(1):169–173. [PubMed] [Google Scholar]
  3. Breslow N., Chan C. W., Dhom G., Drury R. A., Franks L. M., Gellei B., Lee Y. S., Lundberg S., Sparke B., Sternby N. H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977 Nov 15;20(5):680–688. doi: 10.1002/ijc.2910200506. [DOI] [PubMed] [Google Scholar]
  4. Carter H. B., Pearson J. D., Metter E. J., Chan D. W., Andres R., Fozard J. L., Rosner W., Walsh P. C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995 Jul;27(1):25–31. doi: 10.1002/pros.2990270106. [DOI] [PubMed] [Google Scholar]
  5. Comstock G. W., Gordon G. B., Hsing A. W. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):219–221. [PubMed] [Google Scholar]
  6. Devgan S. A., Henderson B. E., Yu M. C., Shi C. Y., Pike M. C., Ross R. K., Reichardt J. K. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate. 1997 Sep 15;33(1):9–12. doi: 10.1002/(sici)1097-0045(19970915)33:1<9::aid-pros2>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  7. Dorgan J. F., Albanes D., Virtamo J., Heinonen O. P., Chandler D. W., Galmarini M., McShane L. M., Barrett M. J., Tangrea J., Taylor P. R. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1069–1074. [PubMed] [Google Scholar]
  8. Flanders W. D. Case-control studies of selected hormones and prostate cancer. An epidemiologic review. Ala J Med Sci. 1986 Oct;23(4):439–443. [PubMed] [Google Scholar]
  9. Gann P. H., Hennekens C. H., Ma J., Longcope C., Stampfer M. J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1118–1126. doi: 10.1093/jnci/88.16.1118. [DOI] [PubMed] [Google Scholar]
  10. Guess H. A., Friedman G. D., Sadler M. C., Stanczyk F. Z., Vogelman J. H., Imperato-McGinley J., Lobo R. A., Orentreich N. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):21–24. [PubMed] [Google Scholar]
  11. Henderson B. E., Bernstein L., Ross R. K., Depue R. H., Judd H. L. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer. 1988 Feb;57(2):216–218. doi: 10.1038/bjc.1988.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hsing A. W., Comstock G. W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993 Jan-Feb;2(1):27–32. [PubMed] [Google Scholar]
  13. Montie J. E., Pienta K. J. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994 Jun;43(6):892–899. doi: 10.1016/0090-4295(94)90163-5. [DOI] [PubMed] [Google Scholar]
  14. Nomura A. M., Kolonel L. N. Prostate cancer: a current perspective. Epidemiol Rev. 1991;13:200–227. doi: 10.1093/oxfordjournals.epirev.a036069. [DOI] [PubMed] [Google Scholar]
  15. Nomura A. M., Stemmermann G. N., Chyou P. H., Henderson B. E., Stanczyk F. Z. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):621–625. [PubMed] [Google Scholar]
  16. Nomura A., Heilbrun L. K., Stemmermann G. N., Judd H. L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res. 1988 Jun 15;48(12):3515–3517. [PubMed] [Google Scholar]
  17. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  18. Reichardt J. K., Makridakis N., Henderson B. E., Yu M. C., Pike M. C., Ross R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995 Sep 15;55(18):3973–3975. [PubMed] [Google Scholar]
  19. Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992 Apr 11;339(8798):887–889. doi: 10.1016/0140-6736(92)90927-u. [DOI] [PubMed] [Google Scholar]
  20. Ross R., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 Jan;76(1):45–48. [PubMed] [Google Scholar]
  21. Shimizu H., Ross R. K., Bernstein L., Yatani R., Henderson B. E., Mack T. M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991 Jun;63(6):963–966. doi: 10.1038/bjc.1991.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Thomas H. V., Reeves G. K., Key T. J. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control. 1997 Nov;8(6):922–928. doi: 10.1023/a:1018476631561. [DOI] [PubMed] [Google Scholar]
  23. Vatten L. J., Ursin G., Ross R. K., Stanczyk F. Z., Lobo R. A., Harvei S., Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):967–969. [PubMed] [Google Scholar]
  24. Vermeulen A., Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992 Apr;74(4):939–942. doi: 10.1210/jcem.74.4.1548361. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES